PDCD1 and gastric cancer: Our previous studies have demonstrated that a higher TMEscore is associated with more favorable progression‐free survival following anti‐PD‐1 immunotherapy combined with chemotherapy, strongly suggesting that TME subtypes can serve as predictive markers for immunotherapy response in gastric cancer.